PE20080691A1 - Profarmacos mejorados de analogos de cc-1065 - Google Patents

Profarmacos mejorados de analogos de cc-1065

Info

Publication number
PE20080691A1
PE20080691A1 PE2007000236A PE2007000236A PE20080691A1 PE 20080691 A1 PE20080691 A1 PE 20080691A1 PE 2007000236 A PE2007000236 A PE 2007000236A PE 2007000236 A PE2007000236 A PE 2007000236A PE 20080691 A1 PE20080691 A1 PE 20080691A1
Authority
PE
Peru
Prior art keywords
indol
subunit
analogue
benc
aminocarbonyloxy
Prior art date
Application number
PE2007000236A
Other languages
English (en)
Inventor
Robert Zhao
Ravi Chari
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20080691A1 publication Critical patent/PE20080691A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN PROFARMACO DE UN AGENTE CITOTOXICO QUE ES UN ANALOGO DE CC-1065 DONDE EL GRUPO FENOLICO DE LA PARTE ALQUILANTE DE LA MOLECULA ESTA PROTEGIDO POR UN GRUPO PROTECTOR TAL COMO UN ACIDO SULFONICO QUE CONTIENE CARBAMATO. EL ANALOGO DE CC-1065 ESTA FORMADO DE UNA PRIMERA SUBUNIDAD DE FORMULA (I) COVALENTEMENTE ENLAZADA A UNA SEGUNDA SUBUNIDAD DE FORMULA (II), (III), (IV), ENTRE OTRAS, A TRAVES DE UN ENLACE AMIDA DESDE EL GRUPO AMINO SECUNDARIO DEL RESTO PIRROLICO DE LA PRIMERA SUBUNIDAD ALCARBOXILO C-2 DE LA SEGUNDA SUBUNIDAD, DONDE Y ES HALURO, METANOSULFONATO, PARATOLUENOSULFONATO, TRIFLUOROMETANOSULFONATO, MONONITRO O DENITROFENOLATO; R, R' Y R1 A R6 SON H, ALQUILO C1-C3, OH, AMINO PRIMARIO, ENTRE OTROS; R7 ES UN GRUPO PROTECTOR DE ACIDO SULFONICO QUE CONTIENE CARBAMATO. SON PROFARMACOS PREFERIDOS: (S)-N-[2-{(1-CLOROMETIL)-1,2-DIHIDRO-5-[(3-HIDROXI-SULFONILFENIL)AMINOCARBONILOXI]-3H-BENC(e)INDOL-3-IL}CARBONIL]-1H-INDOL-5-IL]-5-[(3-METILDITIOPROPANOIL)-AMINO]-1H-INDOL-2-CARBOXAMIDA, (S)-N-[2-{(1-CLOROMETIL)-1,2-DIHIDRO-5-[(3-HIDROXI-SULFONILMETIL-FENIL)AMINOCARBONILOXI]-3H-BENC(e)INDOL-3-IL}CARBONIL]-1H-INDOL-5-IL]-5-[(3-PIRIDILTIO)PROPANOIL]-AMINO}-1H-INDOL-2-CARBOXAMIDA, (S)-N-[2-{(1-CLOROMETIL)-1,2-DIHIDRO-5-[(3-HIDROXI-SULFONILFENIL)AMINOCARBONILOXI]-3H-BENC(e)INDOL-3-IL}CARBONIL]-1H-INDOL-5-IL]-5-[(3-MERCAPTO-PROPANOIL)-AMINO]-1H-INDOL-2-CARBOXAMIDA, ENTRE OTROS.
PE2007000236A 2006-03-07 2007-03-05 Profarmacos mejorados de analogos de cc-1065 PE20080691A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06290379A EP1832577A1 (en) 2006-03-07 2006-03-07 Improved prodrugs of CC-1065 analogs

Publications (1)

Publication Number Publication Date
PE20080691A1 true PE20080691A1 (es) 2008-06-04

Family

ID=36679356

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000236A PE20080691A1 (es) 2006-03-07 2007-03-05 Profarmacos mejorados de analogos de cc-1065

Country Status (18)

Country Link
US (2) US8012978B2 (es)
EP (2) EP1832577A1 (es)
JP (1) JP2009529030A (es)
KR (1) KR20080106919A (es)
AR (1) AR059767A1 (es)
AU (1) AU2007222123A1 (es)
BR (1) BRPI0708654A2 (es)
CA (1) CA2642870A1 (es)
DO (1) DOP2007000041A (es)
EA (1) EA200870327A1 (es)
IL (1) IL193673A0 (es)
MA (1) MA30322B1 (es)
MX (1) MX2008011431A (es)
NO (1) NO20083910L (es)
PE (1) PE20080691A1 (es)
TW (1) TW200813028A (es)
UY (1) UY30190A1 (es)
WO (1) WO2007102069A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US6756397B2 (en) * 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
USRE47123E1 (en) 2006-07-18 2018-11-13 Sanofi EPHA2 receptor antagonist antibodies
CN104013956B (zh) * 2007-01-25 2018-12-18 达娜-法勃肿瘤研究所公司 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
WO2008115404A1 (en) * 2007-03-15 2008-09-25 Ludwing Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
ES2609915T3 (es) 2007-08-14 2017-04-25 Ludwig Institute For Cancer Research Ltd. Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo
US20090155289A1 (en) * 2007-11-01 2009-06-18 Steve Roberts Furin-cleavable peptide linkers for drug-ligand conjugates
AU2009320481C1 (en) 2008-11-03 2016-12-08 Syntarga B.V. Novel CC-1065 analogs and their conjugates
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
TW201117814A (en) 2009-10-02 2011-06-01 Sanofi Aventis New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
LT2560645T (lt) 2010-04-21 2016-10-10 Syntarga B.V. Cc-1065 analogų ir bifunkcinių linkerių konjugatai
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
US9139596B2 (en) 2012-03-30 2015-09-22 The Scripps Research Institute Cyclic prodrugs of duocarmycin analogs
AU2012385228B2 (en) 2012-07-12 2016-10-06 Hangzhou Dac Biotech Co., Ltd Conjugates of cell binding molecules with cytotoxic agents
EP2922818B1 (en) 2012-11-24 2018-09-05 Hangzhou Dac Biotech Co., Ltd Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
KR102323301B1 (ko) 2014-01-10 2021-11-09 비온디스 비.브이. Cys 연결된 항체-약물 접합체의 정제 방법
CA2935430C (en) 2014-01-10 2018-09-18 Synthon Biopharmaceuticals B.V. Duocarmycin adcs for use in treatment of endometrial cancer
DK2948184T3 (en) 2014-01-10 2016-06-27 Synthon Biopharmaceuticals Bv Duocarmycin-ADCs with improved in vivo antitumor activity
WO2015127685A1 (en) 2014-02-28 2015-09-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
AU2015242213A1 (en) 2015-07-12 2018-03-08 Hangzhou Dac Biotech Co., Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
KR20220150408A (ko) 2016-11-14 2022-11-10 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
EP4126833A1 (en) * 2020-03-23 2023-02-08 Helmholtz-Zentrum für Infektionsforschung GmbH N-phenyl-3-mercaptopropanamide derivatives as metallo-beta-lactamase inhibitors for the treatment of bacterial infections
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5278324A (en) * 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
EP0563475B1 (en) * 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
US5646298A (en) 1995-06-07 1997-07-08 Procoron, Inc. Cyclopropylindole prodrugs
US6756397B2 (en) * 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US6534660B1 (en) 2002-04-05 2003-03-18 Immunogen, Inc. CC-1065 analog synthesis

Also Published As

Publication number Publication date
EA200870327A1 (ru) 2009-02-27
UY30190A1 (es) 2008-10-31
AU2007222123A1 (en) 2007-09-13
BRPI0708654A2 (pt) 2011-06-07
EP1832577A1 (en) 2007-09-12
IL193673A0 (en) 2009-05-04
JP2009529030A (ja) 2009-08-13
KR20080106919A (ko) 2008-12-09
DOP2007000041A (es) 2007-10-31
US20090028821A1 (en) 2009-01-29
NO20083910L (no) 2008-12-01
MA30322B1 (fr) 2009-04-01
MX2008011431A (es) 2008-09-22
TW200813028A (en) 2008-03-16
EP1993999A1 (en) 2008-11-26
WO2007102069A1 (en) 2007-09-13
CA2642870A1 (en) 2007-09-13
AR059767A1 (es) 2008-04-30
US20110280890A1 (en) 2011-11-17
US8012978B2 (en) 2011-09-06

Similar Documents

Publication Publication Date Title
PE20080691A1 (es) Profarmacos mejorados de analogos de cc-1065
PE20020276A1 (es) COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
PE20040479A1 (es) Inhibidores de proteasa del vih y composiciones que los contienen
AR071959A1 (es) Derivado de benceno o tiofeno y su uso como inhibidor de vap-1
CO5590904A2 (es) Esteriodes 3-nitrogen-6,7-dioxigeno y usos relacionados con este
AR060545A1 (es) Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas
PE20070138A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
ECSP045317A (es) Piridinoilpiperidinas como agonistas de 5-ht1f
PA8606901A1 (es) Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3
BRPI0500480B8 (pt) processo para a síntese de ivabradina bem como processos para a resolução de amina e para a síntese de composto relacionado com a síntese de ivabradina
AR058618A1 (es) "( indazol -5- il) - pirazinas y (1,3- dihidro- indol-2- ona) - pirazinas para el tratamiento de enfermedades y afecciones mediadas por rho quinasa
PE20071223A1 (es) Procedimiento de preparacion de derivados de acil-amino-alquilen-amida
RS20090249A (en) Spiroketone acetyl-coa carboxylase inhibotors
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
BRPI0500585B8 (pt) processo para a síntese de ivabradina e sais de adição desta com um ácido farmaceuticamente aceitável
TW200600514A (en) Heterocyclic amide compound and use thereof
PE20070321A1 (es) Compuestos heterociclicos como inhibidores de proteasas
CL2003002555A1 (es) Sal de aluminio libre de zirconio que tiene relacion de al: cloruro de 0,5 -2,5: 1, un amortiguador que tiene nitrogeno en una razon respecto al aluminio de 0,05 - 0,25: 1, su ph se encuentra comprendido entre 2 - 4 a una concentracion del 15% y es u
RS52874B (en) THYOPHEN ANALYSIS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
JP2011515483A5 (es)
AR061918A1 (es) Compuesto biciclico que contiene nitrogeno, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
AR053342A1 (es) Quinolonas y naftiridonas 7- maino alquilildenil- heterociclicas
PE20120557A1 (es) Compuestos derivados de (5r)-10, 10-dimetil-7-azadispiro[3.0.4.1]decan-8-carboxamida como inhibidores del virus de la hepatitis c
AR054102A1 (es) Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas

Legal Events

Date Code Title Description
FD Application declared void or lapsed